Novel strategies for treating relapsed/refractory urothelial carcinoma.
Advanced urothelial cancer is associated with a poor prognosis and there has been no substantial progress over the past three decades since the development of platinum-based multiagent chemotherapy. Clinical trials evaluating novel agents and combinations including chemotherapeutic drugs, as well as targeted inhibitors, are desperately needed. With a better understanding of the complex molecular alterations that drive urothelial tumorigenesis, new targets for novel therapeutics are being defined. This article will describe the current state of advanced urothelial cancer treatment and provide a comprehensive discussion of novel agents in development.
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Gopa
G
Iyer
Matthew I
MI
Milowsky
Dean F
DF
Bajorin
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology; D019459:Urothelium / Q000473:pathology